Tiziana CEO buys 14,848 shares at $1.65 each

Tiziana Life Sciences LTD filed a Form 6-K to report that Chief Executive Officer Ivor Elrifi purchased 14,848 shares of Tiziana common stock in the open market at $1.65 per share on September 9, 2025.

Rhea-AI Filing Summary

Tiziana Life Sciences LTD filed a Form 6-K to report that Chief Executive Officer Ivor Elrifi purchased 14,848 shares of Tiziana common stock in the open market at $1.65 per share on September 9, 2025. This transaction increases his total purchased shareholding to 193,848 shares.

The filing also notes that this purchase updates and corrects an earlier press release issued the same day, and includes the related press release as an exhibit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tiziana Life Sciences (TLSA) disclose in this Form 6-K?

Tiziana Life Sciences LTD disclosed that its Chief Executive Officer, Ivor Elrifi, purchased 14,848 shares of Tiziana common stock in the open market at $1.65 per share, bringing his total purchased holdings to 193,848 shares.

How many Tiziana Life Sciences (TLSA) shares did the CEO buy and at what price?

CEO Ivor Elrifi bought 14,848 shares of Tiziana Life Sciences common stock at a price of $1.65 per share in an open market transaction.

What is the CEO’s total purchased shareholding in Tiziana Life Sciences after this transaction?

After this transaction, CEO Ivor Elrifi has purchased a total of 193,848 shares of Tiziana Life Sciences common stock.

Why did Tiziana Life Sciences file this 6-K regarding the CEO share purchase?

The company filed the 6-K to announce and clarify CEO Ivor Elrifi’s share purchase and to correct an earlier press release issued the same day that contained inaccurate information.

Is the press release about the CEO’s share purchase included with the Tiziana Life Sciences 6-K?

Yes. The related press release, dated September 9, 2025, is included as Exhibit 99.1 to the Form 6-K.

Is the information in the Tiziana Life Sciences CEO purchase 6-K considered filed or furnished?

The information in Exhibit 99.1 is being furnished, not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not automatically incorporated by reference into other filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 10:42 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 9, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing that its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open market, correcting todays earlier press release. This brings his current purchased shares total to 193,848.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: September 9, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated September 9, 2025

3